Highlights Y-mAbs Therapeutics, Inc.

Equities

YMAB

US9842411095

Real-time Estimate Cboe BZX Other stock markets 01:55:29 2024-06-10 pm EDT			5-day change	1st Jan Change
12.04 ^USD	+0.54%		-0.17%	+76.69%

Jun. 05	Y-mAbs Therapeutics, Inc. Appoints Norman LaFrance as Chief Development Officer	CI
Jun. 01	Y-mAbs Therapeutics, Inc. Announces Publication of Preclinical GD2-SADA Data	CI

Highlights

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Y-mAbs Therapeutics, Inc. Announces Publication of Preclinical GD2-SADA Data	Jun. 01	CI
Y-mAbs Therapeutics, Inc. Announces New Interim Analysis of Phase 2 Data for Naxitamab At 2024 Asco Annual Meeting	Jun. 01	CI
Earnings Flash (YMAB) Y-MABS THERAPEUTICS Posts Q1 Revenue $19.9M, vs. Street Est of $22.2M	May. 07	MT
Y-mAbs Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	May. 07	CI
Y-mAbs Therapeutics Surges 18% in Premarket Activity Following Q4 Results; Reiterates Anticipated Cash Runway into 2027	Mar. 01	MT
Y-mAbs Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	Feb. 29	CI
Earnings Flash (YMAB) Y-MABS THERAPEUTICS Reports Q4 Revenue $23.4M, vs. Street Est of $21M	Feb. 29	MT
Y-mAbs Therapeutics, Inc. Provides Earnings Guidance for the Year 2024	Feb. 29	CI
Y-mAbs Therapeutics, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	Feb. 29	CI
Y-mAbs Therapeutics to Join NASDAQ Biotechnology Index Dec. 18	Dec. 13	MT
Y-mAbs Therapeutics Q3 Net Loss Narrows, Revenue Rises	Nov. 13	MT
Earnings Flash (YMAB) Y-MABS THERAPEUTICS Posts Q3 Revenue $20.5M, vs. Street Est of $20.9M	Nov. 13	MT
Y-mAbs Therapeutics, Inc. Reiterates Financial Guidance for the Year 2023	Nov. 13	CI
Y-mAbs Therapeutics, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	Nov. 13	CI
Y-mAbs Therapeutics Announces U.S. FDA Clearance of Investigational New Drug Application for CD38-SADA	23-10-18	CI
Y-mAbs Therapeutics, Inc. Announces Publication of Naxitamab-Based Chemoimmunotherapy in Patients with Chemoresistant High-Risk Neuroblastoma	23-10-16	CI
Earnings Flash (YMAB) Y-MABS THERAPEUTICS Posts Q2 Revenue $20.8M, vs. Street Est of $20.3M	23-08-10	MT
Y-mAbs Therapeutics, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	23-08-10	CI
Y-mAbs Therapeutics, Inc. Announces DANYELZA (naxitamab-gqgk) for the Treatment of High-Risk Neuroblastoma Approved in Brazil	23-05-23	CI
Y-mAbs Therapeutics, Inc. Updates Financial Guidance for the Full-Year 2023	23-05-08	CI

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Highlights Y-mAbs Therapeutics, Inc.

Equities

YMAB

US9842411095

Highlights

Filters